LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 186

Search options

  1. Article ; Online: IL-22, a new beacon in gastrointestinal aGVHD.

    Mohty, Mohamad / Malard, Florent

    Blood

    2023  Volume 141, Issue 12, Page(s) 1369–1370

    MeSH term(s) Humans ; Interleukins ; Hematopoietic Stem Cell Transplantation ; Lower Gastrointestinal Tract ; Adrenal Cortex Hormones ; Graft vs Host Disease ; Interleukin-22
    Chemical Substances Interleukins ; Adrenal Cortex Hormones
    Language English
    Publishing date 2023-03-23
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022018934
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Updates in chronic graft-versus-host disease management.

    Malard, Florent / Mohty, Mohamad

    American journal of hematology

    2023  Volume 98, Issue 10, Page(s) 1637–1644

    Abstract: Chronic graft-versus-host disease (cGvHD) remains the most important long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT), but the field has seen significant changes in the last decade. Remarkable advances in the ... ...

    Abstract Chronic graft-versus-host disease (cGvHD) remains the most important long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT), but the field has seen significant changes in the last decade. Remarkable advances in the understanding of the biological pathways of cGvHD, lead to the development of targeted therapy with novel drugs thereby minimizing the exposure to harmful corticosteroids, preserving function and mobility, preventing disability, and improving quality of life (QoL) and overall survival (OS). Steroid-refractory cGvHD management has recently experienced significant improvement since ibrutinib and ruxolitinib were approved for patients that failed at least one line of treatment and belumosudil for patients that failed two lines. These recently approved drugs will be discussed in this review, along with perspectives regarding cGVHD management and additional promising drug in development.
    MeSH term(s) Humans ; Bronchiolitis Obliterans Syndrome ; Quality of Life ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation/adverse effects ; Adrenal Cortex Hormones/therapeutic use ; Chronic Disease
    Chemical Substances Adrenal Cortex Hormones
    Language English
    Publishing date 2023-07-22
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.27040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation.

    Malard, Florent / Jenq, Robert R

    Cancer journal (Sudbury, Mass.)

    2023  Volume 29, Issue 2, Page(s) 75–83

    Abstract: Abstract: Allogeneic hematopoietic cell transplantation (alloHCT) is a standard curative therapy for a variety of benign and malignant hematological diseases. Previously, patients who underwent alloHCT were at high risk for complications with ... ...

    Abstract Abstract: Allogeneic hematopoietic cell transplantation (alloHCT) is a standard curative therapy for a variety of benign and malignant hematological diseases. Previously, patients who underwent alloHCT were at high risk for complications with potentially life-threatening toxicities, including a variety of opportunistic infections as well as acute and chronic manifestations of graft-versus-host disease (GVHD), where the transplanted immune system can produce inflammatory damage to the patient. With recent advances, including newer conditioning regimens, advances in viral and fungal infection prophylaxis, and novel GVHD prophylactic and treatment strategies, improvements in clinical outcomes have steadily improved. One modality with great potential that has yet to be fully realized is targeting the microbiome to further improve clinical outcomes.In recent years, the intestinal microbiota, which includes bacteria, fungi, viruses, and other microbes that reside within the intestinal tract, has become established as a potent modulator of alloHCT outcomes. The composition of intestinal bacteria, in particular, has been found in large multicenter prospective studies to be strongly associated with GVHD, treatment-related mortality, and overall survival. Murine studies have demonstrated a causal relationship between intestinal microbiota injury and aggravated GVHD, and more recently, clinical interventional studies of repleting the intestinal microbiota with fecal microbiota transplantation have emerged as effective therapies for GVHD. How the composition of the intestinal bacterial microbiota, which is often highly variable in alloHCT patients, can modulate GVHD and other outcomes is not fully understood. Recent studies, however, have begun to make substantial headway, including identifying particular bacterial subsets and/or bacterial-derived metabolites that can mediate harm or benefit. Here, the authors review recent studies that have improved our mechanistic understanding of the relationship between the microbiota and alloHCT outcomes, as well as studies that are beginning to establish strategies to modulate the microbiota with the hope of optimizing clinical outcomes.
    MeSH term(s) Animals ; Humans ; Mice ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation/adverse effects ; Microbiota ; Prospective Studies
    Language English
    Publishing date 2023-03-23
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2018400-1
    ISSN 1540-336X ; 1528-9117 ; 1081-4442
    ISSN (online) 1540-336X
    ISSN 1528-9117 ; 1081-4442
    DOI 10.1097/PPO.0000000000000645
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Let's reconstitute microbiota diversity.

    Malard, Florent / Mohty, Mohamad

    Blood

    2021  Volume 137, Issue 11, Page(s) 1442–1444

    MeSH term(s) Humans ; Microbiota
    Language English
    Publishing date 2021-03-18
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2020009963
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Variations of the Relative Parasympathetic Tone Assessed by ANI During Oocyte Retrieval Under Local Anaesthesia with Virtual Reality : A Randomized, Controlled, Monocentric, Open Study.

    Malard, Florent / Moy, Ludovic / Denoual, Vincent / Beloeil, Helene / Leblong, Emilie

    Journal of medical systems

    2024  Volume 48, Issue 1, Page(s) 39

    Abstract: Transvaginal oocyte retrieval is an outpatient procedure performed under local anaesthesia. Hypno-analgesia could be effective in managing comfort during this procedure. This study aimed to assess the effectiveness of a virtual reality headset as an ... ...

    Abstract Transvaginal oocyte retrieval is an outpatient procedure performed under local anaesthesia. Hypno-analgesia could be effective in managing comfort during this procedure. This study aimed to assess the effectiveness of a virtual reality headset as an adjunct to local anaesthesia in managing nociception during oocyte retrieval. This was a prospective, randomized single-centre study including patients undergoing oocyte retrieval under local anaesthesia. Patients were randomly assigned to the intervention group (virtual reality headset + local anaesthesia) or the control group (local anaesthesia). The primary outcome was the efficacy on the ANI
    MeSH term(s) Humans ; Anesthesia, Local ; Oocyte Retrieval/adverse effects ; Oocyte Retrieval/methods ; Prospective Studies ; Pain/etiology ; Virtual Reality
    Language English
    Publishing date 2024-04-05
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 423488-1
    ISSN 1573-689X ; 0148-5598
    ISSN (online) 1573-689X
    ISSN 0148-5598
    DOI 10.1007/s10916-024-02057-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation.

    Battipaglia, Giorgia / Saraceni, Francesco / Malard, Florent

    Frontiers in oncology

    2022  Volume 12, Page(s) 863800

    Language English
    Publishing date 2022-03-21
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.863800
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Increasing Donor Options in Allogenic Hematopoietic Cell Transplantation.

    Mohty, Mohamad / Malard, Florent

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2021  Volume 39, Issue 18, Page(s) 1951–1954

    MeSH term(s) Hematopoietic Stem Cell Transplantation ; Humans ; Tissue Donors
    Language English
    Publishing date 2021-05-04
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.21.00622
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Potential future direction of measurable residual disease evaluation in multiple myeloma.

    Mohty, Mohamad / Avet-Loiseau, Hervé / Malard, Florent / Harousseau, Jean-Luc

    Blood

    2023  Volume 142, Issue 18, Page(s) 1509–1517

    Abstract: Multiple myeloma remains an incurable disease plagued by high relapse rates. Deeper and more sustainable responses, however, have been consistently shown to improve outcomes and could eventually pave the way to achieving a cure. Our understanding of ... ...

    Abstract Multiple myeloma remains an incurable disease plagued by high relapse rates. Deeper and more sustainable responses, however, have been consistently shown to improve outcomes and could eventually pave the way to achieving a cure. Our understanding of disease response has surpassed complete response (CR), because the current definitions are suboptimal, and the treatment goal should aim even beyond stringent CR, toward molecular and flow CR, that is, measurable residual disease (MRD) negativity. It has been more than 20 years since the discrepancy in the outcome between patients in CR with and without MRD has been demonstrated, and the field has come a long way from multiparameter flow cytometry to next-generation flow and next-generation sequencing, able to detect up to a limit of detection of a single myeloma cell from 1 million healthy counterparts. This review aims to summarize the current available data regarding MRD but also its potential future use as a coprimary outcome both in clinical and trial settings as a survival surrogate as well as its use to evaluate treatment efficacy and for adaptive response-based and early-rescue therapy. Furthermore, we discuss whether these concepts are applicable in different settings (eg, newly diagnosed and relapsed/refractory myeloma, patients who are eligible and ineligible for tansplant, and standard- and high-risk disease).
    MeSH term(s) Humans ; Multiple Myeloma/therapy ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local ; Treatment Outcome ; Neoplasm, Residual/diagnosis ; Flow Cytometry
    Language English
    Publishing date 2023-07-04
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2023020284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice.

    Malard, Florent / Gaugler, Béatrice / Mohty, Mohamad

    The Lancet. Haematology

    2022  Volume 9, Issue 10, Page(s) e776–e785

    Abstract: The effect of the gut microbiota on patients' outcomes after allogeneic haematopoietic cell transplantation (HCT) is now well established. In particular, gut microbiota dysbiosis has been associated with acute graft-versus-host disease (GVHD). ... ...

    Abstract The effect of the gut microbiota on patients' outcomes after allogeneic haematopoietic cell transplantation (HCT) is now well established. In particular, gut microbiota dysbiosis has been associated with acute graft-versus-host disease (GVHD). Furthermore, increasing data also suggest an effect of the gut microbiota on outcome after autologous HCT and CAR T cells. In fact, the bacterial gut microbiota interplays with the immune system and contributes to immunological complication and antitumour response to treatment. Therefore, faecal microbiota transplantation has been evaluated in patients with haematological malignancies for various indications, including Clostridioides difficile infection, eradication of multidrug-resistant bacteria, and steroid refractory acute GVHD. In addition, use of prophylactic faecal microbiota transplantation to restore the gut microbiota and improve patients' outcomes is being developed in the setting of allogeneic HCT, but also probably very soon in patients receiving autologous HCT or CAR T cells.
    MeSH term(s) Cell- and Tissue-Based Therapy ; Fecal Microbiota Transplantation/adverse effects ; Graft vs Host Disease/etiology ; Hematologic Neoplasms/therapy ; Humans ; Translational Research, Biomedical
    Language English
    Publishing date 2022-09-29
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2352-3026
    ISSN (online) 2352-3026
    DOI 10.1016/S2352-3026(22)00223-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Management of patients with multiple myeloma during the COVID-19 pandemic.

    Malard, Florent / Mohty, Mohamad

    The Lancet. Haematology

    2020  Volume 7, Issue 6, Page(s) e435–e437

    MeSH term(s) Antineoplastic Agents, Alkylating/therapeutic use ; Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/epidemiology ; Disease Management ; Hematopoietic Stem Cell Transplantation ; Humans ; Melphalan/therapeutic use ; Multiple Myeloma/complications ; Multiple Myeloma/therapy ; Outpatients ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/epidemiology ; Risk Factors ; SARS-CoV-2 ; Steroids/therapeutic use ; Transplantation, Autologous
    Chemical Substances Antineoplastic Agents, Alkylating ; Steroids ; Melphalan (Q41OR9510P)
    Keywords covid19
    Language English
    Publishing date 2020-04-27
    Publishing country England
    Document type Journal Article
    ISSN 2352-3026
    ISSN (online) 2352-3026
    DOI 10.1016/S2352-3026(20)30124-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top